Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy LivaNova (LIVN) stocks in Canada

Learn how to easily invest in LivaNova stocks.

LivaNova is a medical devices business based in the US. LivaNova stocks (LIVN.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $86.59 – a decrease of 9.16% over the previous week. LivaNova employs 4,000 staff and has a trailing 12-month revenue of around $1 billion.

How to buy shares in LivaNova

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – LIVN – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

LivaNova stock price (NASDAQ:LIVN)

Use our graph to track the performance of LIVN stocks over time.

LivaNova shares at a glance

Information last updated 2022-01-25.
Latest market close$74.28
52-week range$61.76 - $93.89
50-day moving average $83.95
200-day moving average $82.86
Wall St. target price$106.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-8.23

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
Wealthsimple Trade
Finder Rating:
3.9 / 5
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
3.8 / 5
$4.99 - $9.99
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
4.1 / 5
Min. $1.00, Max. 0.5%
Stocks, Bonds, Options, ETFs, Currencies, Futures
CIBC Investor's Edge
Finder Rating:
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Finder Rating:
4.2 / 5
$4.95 - $9.95
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get up to $5,000 cash back. Conditions apply. Offer ends March 1, 2022.

Compare up to 4 providers

Online stock trading

Is it a good time to buy LivaNova stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

LivaNova price performance over time

Historical closes compared with the close of $74.28 from 2022-01-26

1 week (2022-01-21) -5.24%
1 month (2021-12-24) N/A
3 months (2021-10-28) -4.04%
6 months (2021-07-28) -13.56%
1 year (2021-01-28) 15.00%
2 years (2020-01-28) 7.84%
3 years (2019-01-28) 89.11
5 years (2017-01-27) 54.88%

Is LivaNova under- or over-valued?

Valuing LivaNova stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of LivaNova's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

LivaNova's PEG ratio

LivaNova's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 5.0239. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into LivaNova's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

LivaNova's EBITDA

LivaNova's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $64.3 million.

The EBITDA is a measure of a LivaNova's overall financial performance and is widely used to measure a its profitability.

LivaNova financials

Revenue TTM $1 billion
Operating margin TTM 0.97%
Gross profit TTM $605.3 million
Return on assets TTM 0.27%
Return on equity TTM -30.53%
Profit margin -39.34%
Book value $24.66
Market capitalisation $4.2 billion

TTM: trailing 12 months

LivaNova share dividends

We're not expecting LivaNova to pay a dividend over the next 12 months.

LivaNova share price volatility

Over the last 12 months, LivaNova's shares have ranged in value from as little as $61.76 up to $93.89. A popular way to gauge a stock's volatility is its "beta".

LIVN.US volatility(beta: 0.89)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while LivaNova's is 0.8936. This would suggest that LivaNova's shares are less volatile than average (for this exchange).

LivaNova overview

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients. It also provides surgical tissue and mechanical valve replacements, and repair products for damaged or diseased heart valves, such as self-anchoring tissue heart, tissue heart, and mechanical heart valves, as well as heart valve repair products; and temporary extracorporeal cardiopulmonary life support solutions for critically ill patients. The NM segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers.

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site